BrainAurora Partners with DODR to Launch Cognitive Digital Therapeutics in Malaysia and Southeast Asia

An update from BrainAurora Medical Technology Limited ( (HK:6681) ) is now available.

BrainAurora Medical Technology Limited has signed a strategic cooperation agreement with DODR Technology Ltd., a subsidiary of China Silk Road Group, to localise, clinically validate and commercialise its cognitive impairment digital therapeutics in Malaysia and, subsequently, wider Southeast Asia. Leveraging DODR and Silk Road Group’s established digital trade, healthcare platforms and government and hospital networks in the region, the partners plan to build a specialised cognitive impairment lab in Malaysia, pursue national innovation pilot projects, conduct hospital-based clinical trials, and jointly promote market expansion into countries including Indonesia, Thailand and Vietnam, positioning BrainAurora for international growth amid rising mental health and ageing-related care needs.

The most recent analyst rating on (HK:6681) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on BrainAurora Medical Technology Limited stock, see the HK:6681 Stock Forecast page.

More about BrainAurora Medical Technology Limited

BrainAurora Medical Technology Limited is a China-based medical technology company focused on digital therapeutics for cognitive impairment. Its core offering, the Brain Function Information Management Platform Software System, is the first cognitive impairment digital therapeutics product to secure regulatory approval in China and has been included in provincial medical insurance reimbursement lists across 30 provinces, underscoring its traction in the domestic digital health and neurocognitive care market.

Average Trading Volume: 19,548,091

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$5.37B

Learn more about 6681 stock on TipRanks’ Stock Analysis page.